Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 3

3(42.9%)

7Total

Phase 2(4)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04644289Phase 2Recruiting

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

Role: lead

NCT05903833Phase 2Recruiting

Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

Role: lead

NCT05126342Phase 2Withdrawn

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Role: lead

NCT03353831Phase 3Completed

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Role: lead

NCT04274426Phase 2Active Not Recruiting

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Role: lead

NCT06068738Terminated

Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer

Role: collaborator

NCT03690739Phase 3Terminated

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Role: lead

NCT01837251Phase 3Completed

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Role: lead

NCT02222883Completed

Prevalence of BRCA in Patients With Ovarian Cancer

Role: lead

All 9 trials loaded